Cue Biopharma logo
Cue Biopharma CUE
$ 4.2 -7.69%
report update icon

Quarterly report 2026-Q3
added 11-16-2026

Cue Biopharma Market Cap | CUE

As of November 22, 2026 Cue Biopharma has a market cap of $ 398 M


Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]

Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.

This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.

Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.

Annual Market Cap Cue Biopharma

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
29.4 M 51.3 M 86.5 M 108 M 354 M 388 M 337 M 101 M 311 M - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
388 M 29.4 M 196 M

References

  1. Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.

Market Cap of other stocks in the Biotechnology industry

Issuer Market Cap Price % 24h Market Cap Country
Reata Pharmaceuticals Reata Pharmaceuticals
RETA
1.64 B - - $ 6.29 B usaUSA
PainReform Ltd. PainReform Ltd.
PRFX
1.72 M $ 0.47 -24.53 % $ 305 K israelIsrael
iTeos Therapeutics iTeos Therapeutics
ITOS
293 M - - $ 411 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
4.81 M $ 1.44 -2.03 % $ 2.37 M israelIsrael
PolarityTE PolarityTE
PTE
4.32 M - -0.82 % $ 1.78 M usaUSA
Kronos Bio Kronos Bio
KRON
69.3 M - 1.49 % $ 50.8 M usaUSA
Cullinan Management Cullinan Management
CGEM
898 M $ 8.9 -1.93 % $ 536 M usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
4.39 B $ 39.15 0.57 % $ 3.52 B schweizSchweiz
Advaxis Advaxis
ADXS
1.87 M - -9.65 % $ 45.9 M usaUSA
Stoke Therapeutics Stoke Therapeutics
STOK
2.01 B $ 26.77 -0.59 % $ 1.59 B usaUSA
Trevena Trevena
TRVN
5.09 M - -46.58 % $ 31.8 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
49.1 M - -10.95 % $ 876 K usaUSA
Molecular Templates Molecular Templates
MTEM
10.1 M - -23.43 % $ 495 K usaUSA
Oncorus Oncorus
ONCR
8.55 K - -8.54 % $ 3.19 M usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
15.4 M $ 0.07 9.81 % $ 855 K usaUSA
Novan Novan
NOVN
26.2 M - -24.84 % $ 2.64 M usaUSA
CohBar CohBar
CWBR
5.31 M - -15.44 % $ 2.2 M usaUSA
NeuBase Therapeutics NeuBase Therapeutics
NBSE
6.27 M - -1.56 % $ 12.3 M usaUSA
Epizyme Epizyme
EPZM
126 M - - $ 249 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
5.65 B - -6.81 % $ 3.04 B usaUSA
Scopus BioPharma Scopus BioPharma
SCPS
3.8 M - -48.37 % $ 3.71 M usaUSA
Nabriva Therapeutics plc Nabriva Therapeutics plc
NBRV
4.1 M - - $ 4.55 M irlandaIrlanda
Annovis Bio Annovis Bio
ANVS
51.8 M $ 0.71 -3.81 % $ 14.6 M usaUSA
scPharmaceuticals scPharmaceuticals
SCPH
210 M - - $ 218 M usaUSA
Entasis Therapeutics Holdings Entasis Therapeutics Holdings
ETTX
73.7 M - - $ 105 M usaUSA
Athersys Athersys
ATHX
8.07 M - 3.77 % $ 22.4 M usaUSA
Global Blood Therapeutics Global Blood Therapeutics
GBT
1.82 B - - $ 4.62 B usaUSA
Inozyme Pharma Inozyme Pharma
INZY
297 M - - $ 207 M usaUSA
NanoString Technologies NanoString Technologies
NSTG
459 M - -37.43 % $ 5.1 M usaUSA
Humanigen Humanigen
HGEN
12.5 M - -81.12 % $ 4.28 M usaUSA
CNS Pharmaceuticals CNS Pharmaceuticals
CNSP
1.06 M $ 3.56 -9.07 % $ 1.58 M usaUSA
Sorrento Therapeutics Sorrento Therapeutics
SRNE
746 M - -29.58 % $ 126 M usaUSA
Surface Oncology Surface Oncology
SURF
40.7 M - - $ 59.7 M usaUSA
Sierra Oncology Sierra Oncology
SRRA
288 M - -0.05 % $ 1.34 B canadaCanada
Vaccinex Vaccinex
VCNX
2.96 M - -61.37 % $ 654 K usaUSA
Nymox Pharmaceutical Corporation Nymox Pharmaceutical Corporation
NYMX
18.7 M - -19.68 % $ 18.4 M canadaCanada
Jounce Therapeutics Jounce Therapeutics
JNCE
47.5 M - - $ 98.4 M usaUSA
Cocrystal Pharma Cocrystal Pharma
COCP
11.4 M $ 0.93 -4.11 % $ 10.5 M usaUSA
Fortress Biotech Fortress Biotech
FBIO
77.8 M $ 1.89 6.78 % $ 52.7 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
16.7 M - -24.86 % $ 820 K usaUSA
Longeveron Longeveron
LGVN
16.9 B $ 1.65 -9.34 % $ 29 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
664 K - -11.43 % $ 502 K usaUSA
Immunic Immunic
IMUX
145 M $ 7.0 -5.28 % $ 1.09 B usaUSA
Immunovant Immunovant
IMVT
6.49 B $ 31.74 -2.4 % $ 5.79 B usaUSA
Mersana Therapeutics Mersana Therapeutics
MRSN
60 M - - $ 3.56 B usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
8.08 B $ 6.83 1.71 % $ 460 B britainBritain
MediWound Ltd. MediWound Ltd.
MDWD
131 M $ 13.59 0.33 % $ 370 M israelIsrael
CymaBay Therapeutics CymaBay Therapeutics
CBAY
3.43 B - - $ 3.45 B usaUSA
Freeline Therapeutics Holdings plc Freeline Therapeutics Holdings plc
FRLN
261 M - - $ 384 M britainBritain
Keros Therapeutics Keros Therapeutics
KROS
513 M $ 11.04 -3.07 % $ 411 M usaUSA